Appeal 2007-0860
Application 10/148,535
13. Of the 30 patients in Wroblewski’s study, “4 had a higher seizure
frequency on methylphenidate than off methylphenidate; 13 had a lower
seizure frequency . . .; 13 experienced no change,” leading Wroblewski to
conclude: “Overall, . . . the findings demonstrated a trend toward a lower
incidence of seizures in patients receiving methylphenidate.” (Id. at 88
(emphasis added.)
14. According to Wroblewski, this finding of lower seizure frequency
is “not a unique finding.” (Id. (citing Evans et al., 2 J. Head Trauma
Rehabilitation 29-33 (1987) (“Evans”); Livingston et al., 32 J. Pediatrics
490-94 (1948) (“Livingston”).)
15. Indeed, Livingston discloses a study in which 85 epileptic
patients, primarily children, were treated with other stimulants, benzedrine
and dexedrine; “the seizures were controlled in 38 per cent and markedly or
moderately improved in 20 per cent.” (Livingston, at 494.)
16. Evans links methylphenidate to benzedrine and dexedrine by
noting that the “therapeutic effectiveness of psychostimulant compounds
(methylphenidate hydrochloride, dextroamphetamine sulfate, pemoline) is
well established, particularly for conditions of attention deficit disorder.”
(Evans, at 29-30.)
17. Evans continues: “From a clinical standpoint alone, it is easy to
draw parallels between ADD and TBI” (Traumatic Brain Injury). (Evans, at
30.)
18. Evans then further supports drawing such parallels by turning to
the pharmacology of stimulants, i.e., dopamine antagonism. (Evans, at 30.)
15
Page: Previous 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Next
Last modified: September 9, 2013